ZBIO - Zenas BioPharma, Inc.

QQQ $ 628.80 $ 0.00 (0 %)

DIA $ 476.51 $ 0.00 (0 %)

SPY $ 685.38 $ 0.00 (0 %)

TLT $ 91.96 $ 0.00 (0 %)

GLD $ 360.23 $ 0.00 (0 %)

Previous Close

$ 31.8

Open

$ 28.05

Bid

$ 31.91 x 10

Ask

$ 33.49 x 100

Day's Range

-- - --

52 Week Range

$ 5.83 - $ 34.33

Volume

3,138,747

Average Volume

Market Cap

1.33B

Beta (5Y Monthly)

$ 0.77

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-12-2025	06-30-2025	10-Q
2	05-15-2025	03-31-2025	10-Q
3	03-11-2025	12-31-2024	10-K
4	11-12-2024	09-30-2024	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

12 Health Care Stocks Moving In Monday's I...
10/27/2025 17:05:57

12 Health Care Stocks Moving In Monday's P...
10/27/2025 12:06:22

Zenas BioPharma Announces Obexelimab Met P...
10/27/2025 11:10:03

Zenas Biopharma Files For Shelf Of Up To 6...
10/21/2025 20:53:07

- SEC Filing

Wedbush Maintains Outperform on Zenas BioP...
10/09/2025 13:07:51

Wedbush analyst Martin Fan maintains Zenas BioPharma (NASDAQ:ZBIO) with a Outperform and raises the price target from $35 t...

HC Wainwright & Co. Reiterates Buy on Zena...
10/09/2025 10:16:07

HC Wainwright & Co. analyst Matthew Caufield reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Buy and maintains $30 price...

Zenas Biopharma Files For At-The-Market Of...
10/08/2025 20:37:28

We may offer and sell from time to time, in one or more series or issuances and in an amount and on terms that we will determin...

zenas-biopharma-raises-120-million-to-secure-global-rights-to-multiple-sclerosis-drug

Zenas Biopharma Raises $120 Million To Sec...
10/08/2025 17:56:11

Zenas BioPharma secures global rights to orelabrutinib in multiple sclerosis, expands autoimmune pipeline, and raises $120 mill...

Zenas BioPharma Secures Global Rights To I...
10/08/2025 09:05:14

Zenas BioPharma, Inc. ("Zenas," "Zenas BioPharma" or the "Company") (NASDAQ:ZBIO) and InnoCare Pharma L...

Royalty Pharma To Provide Up To $300M In F...
09/02/2025 11:10:11

Zenas BioPharma Q2 EPS $(1.25) Misses $(1....
08/12/2025 11:14:13

Zenas BioPharma (NASDAQ:ZBIO) reported quarterly losses of $(1.25) per share which missed the analyst consensus estimate of $(1...

HC Wainwright & Co. Reiterates Buy on Zena...
05/16/2025 11:06:35

HC Wainwright & Co. analyst Matthew Caufield reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Buy and maintains $30 price...

Zenas BioPharma Q1 EPS $(0.80) Beats $(1.0...
05/15/2025 11:15:30

Zenas BioPharma (NASDAQ:ZBIO) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate of $(1.0...

excelerate-energy-mediaalpha-and-other-big-stocks-moving-lower-in-tuesdays-pre-market-session

Excelerate Energy, MediaAlpha And Other Bi...
04/01/2025 11:56:53

why-pvh-shares-are-trading-higher-by-around-15-here-are-20-stocks-moving-premarket

Why PVH Shares Are Trading Higher By Aroun...
04/01/2025 09:29:54

zenas-biopharma-gains-outperform-rating-from-analyst-as-key-autoimmune-trials-progress

Zenas BioPharma Gains Outperform Rating Fr...
03/20/2025 18:54:43

Wedbush initiates coverage on Zenas BioPharma, citing strong potential for obexelimab in autoimmune diseases, with key clinical...

Wedbush Initiates Coverage On Zenas BioPha...
03/20/2025 11:55:41

Wedbush analyst Martin Fan initiates coverage on Zenas BioPharma (NASDAQ:ZBIO) with a Outperform rating.

Guggenheim Reiterates Buy on Zenas BioPhar...
03/12/2025 13:52:26

Guggenheim analyst Yatin Suneja reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Buy and maintains $45 price target.

HC Wainwright & Co. Reiterates Buy on Zena...
03/12/2025 11:26:46

HC Wainwright & Co. analyst Matthew Caufield reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Buy and maintains $30 price...

Zenas BioPharma Reports Strong 2024 Moment...
02/05/2025 12:24:35

- Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD-19 x FcγRIIb inhibitor of B cell function--Topline results fr...